3
|
Sgroi D, Carney E, Richardson E, Steffel L, Binns SN, Finkelstein DM, Shepherd LE, Kesty NC, Schnabel C, Erlander MG, Ingle JN, Porter P, Paik S, Muss HB, Pritchard KI, Tu D, Goss PE. Prediction of late recurrences by breast cancer index in the NCIC CTG MA.17 cohort. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.27_suppl.2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2 Background: The MA.17 trial demonstrated that extended adjuvant endocrine therapy with letrozole after 5-y of tamoxifen markedly reduced the risk of recurrence in women with ER+ early stage breast cancer. This trial provides an opportunity to assess the ability of biomarkers to predict late recurrences in ER+ breast cancer. The Breast Cancer Index (BCI), a continuous risk index based on the combination of HOXB13:IL17BR (H:I) and the molecular grade index (MGI), estimates the individual risk of recurrence in ER+ breast cancer patients. In this study, the prognostic utility of BCI to predict late recurrences was examined. Methods: FFPE tumor blocks were collected from patients who experienced a breast cancer recurrence up to unblinding of MA.17. Controls were matched 2:1 for age, tumor size, nodal status and prior chemotherapy, and were disease free for longer than cases. All cases were reviewed for standard histopathology and evaluated using the real-time RT-PCR BCI assay. Results: Patient characteristics for the case-control study were similar to that from the overall study. Characteristics for cases (N=83) and controls (N=166) were not significantly different except for treatment. A higher percentage of controls compared to cases tended to be categorized as low risk by BCI (58% vs 43%), while a lower percentage of controls than cases tended to be categorized as high risk by BCI (34% vs 24%). In univariate analysis, treatment, BCI, H:I and HOXB13, but not tumor grade or MGI, were significant predictors of late recurrence. After adjusting for standard variables (age, tumor grade and treatment), BCI (OR 2.37; P=0.03), H:I (OR 2.55; P=0.04) and HOXB13 (OR 1.35; P=0.02) remained significant predictors of recurrence. HOXB13 expression at diagnosis predicted patient benefit from extended endocrine therapy with letrozole. Conclusions: In this case-controlled study, the data demonstrate that BCI is a significant predictor of late recurrences in ER+ patients following 5-y of tamoxifen. The prognostic performance of BCI to predict late recurrences was largely dependent on HOXB13 expression. The integration of H:I and MGI within BCI provides prognostic utility for both early and late recurrences.
Collapse
Affiliation(s)
- D. Sgroi
- Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Queen's University, Kingston, ON, Canada; bioTheranostics, Inc., San Diego, CA; Mayo Clinic, Rochester, MN; Fred Hutchinson Cancer Research Center, Seattle, WA; National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada; NCIC Clinical Trials Group, Kingston, ON,
| | - E. Carney
- Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Queen's University, Kingston, ON, Canada; bioTheranostics, Inc., San Diego, CA; Mayo Clinic, Rochester, MN; Fred Hutchinson Cancer Research Center, Seattle, WA; National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada; NCIC Clinical Trials Group, Kingston, ON,
| | - E. Richardson
- Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Queen's University, Kingston, ON, Canada; bioTheranostics, Inc., San Diego, CA; Mayo Clinic, Rochester, MN; Fred Hutchinson Cancer Research Center, Seattle, WA; National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada; NCIC Clinical Trials Group, Kingston, ON,
| | - L. Steffel
- Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Queen's University, Kingston, ON, Canada; bioTheranostics, Inc., San Diego, CA; Mayo Clinic, Rochester, MN; Fred Hutchinson Cancer Research Center, Seattle, WA; National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada; NCIC Clinical Trials Group, Kingston, ON,
| | - S. N. Binns
- Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Queen's University, Kingston, ON, Canada; bioTheranostics, Inc., San Diego, CA; Mayo Clinic, Rochester, MN; Fred Hutchinson Cancer Research Center, Seattle, WA; National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada; NCIC Clinical Trials Group, Kingston, ON,
| | - D. M. Finkelstein
- Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Queen's University, Kingston, ON, Canada; bioTheranostics, Inc., San Diego, CA; Mayo Clinic, Rochester, MN; Fred Hutchinson Cancer Research Center, Seattle, WA; National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada; NCIC Clinical Trials Group, Kingston, ON,
| | - L. E. Shepherd
- Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Queen's University, Kingston, ON, Canada; bioTheranostics, Inc., San Diego, CA; Mayo Clinic, Rochester, MN; Fred Hutchinson Cancer Research Center, Seattle, WA; National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada; NCIC Clinical Trials Group, Kingston, ON,
| | - N. C. Kesty
- Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Queen's University, Kingston, ON, Canada; bioTheranostics, Inc., San Diego, CA; Mayo Clinic, Rochester, MN; Fred Hutchinson Cancer Research Center, Seattle, WA; National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada; NCIC Clinical Trials Group, Kingston, ON,
| | - C. Schnabel
- Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Queen's University, Kingston, ON, Canada; bioTheranostics, Inc., San Diego, CA; Mayo Clinic, Rochester, MN; Fred Hutchinson Cancer Research Center, Seattle, WA; National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada; NCIC Clinical Trials Group, Kingston, ON,
| | - M. G. Erlander
- Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Queen's University, Kingston, ON, Canada; bioTheranostics, Inc., San Diego, CA; Mayo Clinic, Rochester, MN; Fred Hutchinson Cancer Research Center, Seattle, WA; National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada; NCIC Clinical Trials Group, Kingston, ON,
| | - J. N. Ingle
- Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Queen's University, Kingston, ON, Canada; bioTheranostics, Inc., San Diego, CA; Mayo Clinic, Rochester, MN; Fred Hutchinson Cancer Research Center, Seattle, WA; National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada; NCIC Clinical Trials Group, Kingston, ON,
| | - P. Porter
- Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Queen's University, Kingston, ON, Canada; bioTheranostics, Inc., San Diego, CA; Mayo Clinic, Rochester, MN; Fred Hutchinson Cancer Research Center, Seattle, WA; National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada; NCIC Clinical Trials Group, Kingston, ON,
| | - S. Paik
- Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Queen's University, Kingston, ON, Canada; bioTheranostics, Inc., San Diego, CA; Mayo Clinic, Rochester, MN; Fred Hutchinson Cancer Research Center, Seattle, WA; National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada; NCIC Clinical Trials Group, Kingston, ON,
| | - H. B. Muss
- Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Queen's University, Kingston, ON, Canada; bioTheranostics, Inc., San Diego, CA; Mayo Clinic, Rochester, MN; Fred Hutchinson Cancer Research Center, Seattle, WA; National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada; NCIC Clinical Trials Group, Kingston, ON,
| | - K. I. Pritchard
- Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Queen's University, Kingston, ON, Canada; bioTheranostics, Inc., San Diego, CA; Mayo Clinic, Rochester, MN; Fred Hutchinson Cancer Research Center, Seattle, WA; National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada; NCIC Clinical Trials Group, Kingston, ON,
| | - D. Tu
- Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Queen's University, Kingston, ON, Canada; bioTheranostics, Inc., San Diego, CA; Mayo Clinic, Rochester, MN; Fred Hutchinson Cancer Research Center, Seattle, WA; National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada; NCIC Clinical Trials Group, Kingston, ON,
| | - P. E. Goss
- Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Queen's University, Kingston, ON, Canada; bioTheranostics, Inc., San Diego, CA; Mayo Clinic, Rochester, MN; Fred Hutchinson Cancer Research Center, Seattle, WA; National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada; NCIC Clinical Trials Group, Kingston, ON,
| |
Collapse
|